How VYRSA Turned One Tiny Joint Into a $75 Million Bet

VYRSA built a three-product answer to a stubborn source of back pain, won FDA clearance for a stranger kind of implant, and sold to Nevro before its third birthday. The playbook is compact: license hard science, simplify the procedure, and let a bigger sales force carry it.